undamentalytics Newsletter
Sign in

Trisalus Life Sciences, Inc. (TLSI) stock

Add to watchlist

Add holding +

NASDAQ: TLSI Nasdaq Health Care Equipment Next results ~November 10, 2026

D Fundamentals grade

Trisalus Life Sciences, Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$1.5

Forward price-to-sales vs peers

Base case. Range ~$1.5–$5.6. Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Trisalus Life Sciences, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders6 buying, 5 selling12 purchases and 18 sales by directors and officers, last 12 monthsInsider trades
  • Funds56 adding, 25 cuttingOf 11 active managers that changed their stake, 4 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Trisalus Life Sciences files

Where Trisalus Life Sciences stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $45m, up 25.2% on a year earlier, slower than the 39.6% growth a quarter earlier. Free-cash-flow margin rose to -51.6% from -81.3% a year earlier. Operating margin widened to -67.7% from -86.1%. The diluted share count is up 73.8% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 3 of our 6 financial-health checks.

Source: 10-Q filed August 6, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 10, 2026 (estimated)

Trisalus Life Sciences, Inc.'s trailing-twelve-month revenue grew 25.2% year on year, with a free-cash-flow margin of -51.6%. Where it stands out: gross margin of 85.8% ranks 13 of 123 health care equipment companies we cover. Where it lags: change in share count of 73.8% ranks 111 of 115 health care equipment companies we cover.

Current signal Revenue growth decelerating: TTM revenue growth slowed to 25.2% (-14.4pp vs the prior quarter), the 2nd consecutive quarterly slowdown.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 25.2% over the last 12 months, against a median of 9.1% for health care equipment companies we cover.
  • Margins widening. Operating margin is up 18.4 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Growth slowing. The growth rate is 14.4 points lower than a quarter earlier.
  • Loss-making. Operating margin is -67.7%: costs exceed revenue.
  • Burning cash. Free cash flow was -51.6% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 23.6% of revenue, against a median of 6.1% for health care equipment companies we cover: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 73.8% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 79% and a beta of 1.2 against the S&P 500.

Latest results: FY2026 Q2

Filed August 6, 2026
Earnings per share
-$0.16 against an average estimate of -$0.15: missed by 3.2%
Revenue
$11m, up 1.7% on a year earlier
Share reaction
+21.4% in the first session after the results on August 6, 2026, against +0.5% for the S&P 500
Next report
November 10, 2026

Trisalus Life Sciences' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-1.9%
  • 1 week+0.3%
  • 1 month-16.0%
  • This year-48.0%
  • 1 year-23.4%
  • 5 years-63.5%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$45.1M
Operating margin
-67.7%
Net margin
-62.6%
EPS (TTM, diluted)
$-0.56

Growth

Revenue growth
+25.2%
Change in growth rate
−14.4 pts
Share count change
+73.8%

Cash

Free cash flow (TTM)
-$23.3M
FCF margin
-51.6%
Stock pay % of revenue
23.6%

Earnings

Last results
August 6, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Trisalus Life Sciences, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Trisalus Life Sciences, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.6%: the 10-year Treasury yield (4.9%) plus a beta of 1.04 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$0.4 Left out: out of range vs price (0.11x)
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$1.5 ~$1.6–$5.6 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$1.5 ~$1.5–$5.6 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Trisalus Life Sciences, Inc. with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 2022202320242025Now
Share price$10.03$8.45$5.01$6.98$3.63
Market value$3m$79m$127m$265m$182m
+ Net debt (− = net cash)−$8m−$12m$14m$13m−$13m
Enterprise value−$5m$68m$140m$277m$169m
Multiples
Price / sales 0.3x4.3x4.3x5.9x4.0x
Price / earnings —————
Price / free cash flow —————
EV / EBITDA —————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Low.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 10, 2026, before the open. Analysts expect revenue of $14m for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.33 +82% $53m +18%
Next −$0.26 +20% $75m +40%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +13.8% on 90 days ago. In the last 30 days, 0 analysts raised Trisalus Life Sciences, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Trisalus Life Sciences, Inc., last 90 days
−$0.40 −$0.30 −$0.20 −$0.10 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.29 Current fiscal year, 60 days ago: −$0.29 Current fiscal year, 30 days ago: −$0.33 Current fiscal year, 7 days ago: −$0.33 Current fiscal year, Now: −$0.33 −$0.33 Next fiscal year, 90 days ago: −$0.16 Next fiscal year, 60 days ago: −$0.14 Next fiscal year, 30 days ago: −$0.26 Next fiscal year, 7 days ago: −$0.26 Next fiscal year, Now: −$0.26 −$0.26

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.29−$0.16
60 days ago −$0.29−$0.14
30 days ago −$0.33−$0.26
7 days ago −$0.33−$0.26
Now −$0.33−$0.26

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.15 −$0.16 −3.2%
Dec 2025 −$0.13 −$0.05 +61.5%
Sept 2025 −$0.17 −$0.87 −425.7%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

5 analysts, Oct 2026
Buy5100%
Hold00%
Sell00%

Monthly trend

  1. Oct 2026145
  2. Sep 2026134
  3. Aug 2026134

Counts of recommendations published by analysts covering Trisalus Life Sciences, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
7.4%
of tradable shares
Days to cover
7.52
at average volume
Short interest, 1 month
+3%
to October 15, 2026
Held by institutions
36%
of shares
Held by insiders
34.0%
of shares
Employees
102
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

Return and risk by year

Calendar year 20222023202420252026 to date
Return
TLSI+2%−16%−41%+39%−48%
Industry peers (median)−37%−8%−19%−16%−13%
S&P 500−18%+26%+25%+18%+11%
Months that ended higher
TLSI67%50%50%58%36%
S&P 50042%67%75%75%46%
Largest fall from a high during the year
TLSI−6%−70%−65%−38%−64%
S&P 500−25%−10%−8%−19%−9%

Worst fall since February 8, 2021: 79% from August 11, 2023 to May 14, 2026. Getting back needed a 376% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$2.52 – $7.50
From 52-week high
−51.6%
vs 50-day average
−17.5%
vs 200-day average
−17.3%
Volatility (1 year)
79%
Beta vs S&P 500
1.18

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
8 up, 4 down
typical move ±10.7%
After a week
6 up, 6 down
typical move ±13.5%
After a month
7 up, 5 down
typical move ±18.9%
Results releasedNext dayS&P 500 next day5 days21 days
August 6, 2026 +21.4% +0.5% +21.9% +8.2%
May 12, 2026 −41.2% +0.4% −30.6% −19.8%
March 5, 2026 −10.7% −1.9% −18.0% −18.4%
January 12, 2026 +1.7% 0.0% −9.3% −17.2%
November 13, 2025 +3.2% −1.7% +12.2% +65.4%
August 12, 2025 +10.6% +1.4% +30.3% +31.1%
May 15, 2025 +4.9% +1.1% +9.2% +12.4%
April 30, 2025 −11.0% +0.7% −9.1% −12.6%
March 27, 2025 +0.7% −2.3% −6.5% +2.5%
February 3, 2025 +4.7% 0.0% +9.2% +12.5%
January 23, 2025 +5.7% +0.3% +4.3% +12.4%
November 14, 2024 −12.7% −1.9% −1.6% −13.8%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Trisalus Life Sciences, Inc. in five measures

Fundamentals grade D
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Trisalus Life Sciences, Inc.
$10M $20M $30M $40M $50M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $16M Revenue (TTM), FY23 Q4: $18.5M Revenue (TTM), FY24 Q1: $22M Revenue (TTM), FY24 Q2: $24.7M Revenue (TTM), FY24 Q3: $26.9M Revenue (TTM), FY24 Q4: $29.4M Revenue (TTM), FY25 Q1: $32.1M Revenue (TTM), FY25 Q2: $36M Revenue (TTM), FY25 Q3: $40.2M Revenue (TTM), FY25 Q4: $45.2M Revenue (TTM), FY26 Q1: $44.9M Revenue (TTM), FY26 Q2: $45.1M $45.1M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $16M
FY23 Q4 $18.5M
FY24 Q1 $22M
FY24 Q2 $24.7M
FY24 Q3 $26.9M
FY24 Q4 $29.4M
FY25 Q1 $32.1M
FY25 Q2 $36M
FY25 Q3 $40.2M
FY25 Q4 $45.2M
FY26 Q1 $44.9M
FY26 Q2 $45.1M
Revenue growth, TTM YoY Trisalus Life Sciences, Inc.
20% 40% 60% 80% FY24 Q2 FY24 Q4 FY25 Q2 FY25 Q4 FY26 Q2 Revenue growth, TTM YoY, FY24 Q2: 67.8% Revenue growth, TTM YoY, FY24 Q3: 67.9% Revenue growth, TTM YoY, FY24 Q4: 59.0% Revenue growth, TTM YoY, FY25 Q1: 46.2% Revenue growth, TTM YoY, FY25 Q2: 45.5% Revenue growth, TTM YoY, FY25 Q3: 49.5% Revenue growth, TTM YoY, FY25 Q4: 53.4% Revenue growth, TTM YoY, FY26 Q1: 39.6% Revenue growth, TTM YoY, FY26 Q2: 25.2% 25.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY24 Q2 67.8%
FY24 Q3 67.9%
FY24 Q4 59.0%
FY25 Q1 46.2%
FY25 Q2 45.5%
FY25 Q3 49.5%
FY25 Q4 53.4%
FY26 Q1 39.6%
FY26 Q2 25.2%
Operating margin (TTM) Trisalus Life Sciences, Inc.
-400% -300% -200% -100% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -324.3% Operating margin (TTM), FY23 Q4: -294.0% Operating margin (TTM), FY24 Q1: -254.6% Operating margin (TTM), FY24 Q2: -213.1% Operating margin (TTM), FY24 Q3: -159.3% Operating margin (TTM), FY24 Q4: -122.9% Operating margin (TTM), FY25 Q1: -99.0% Operating margin (TTM), FY25 Q2: -86.1% Operating margin (TTM), FY25 Q3: -77.7% Operating margin (TTM), FY25 Q4: -59.7% Operating margin (TTM), FY26 Q1: -62.4% Operating margin (TTM), FY26 Q2: -67.7% -67.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -324.3%
FY23 Q4 -294.0%
FY24 Q1 -254.6%
FY24 Q2 -213.1%
FY24 Q3 -159.3%
FY24 Q4 -122.9%
FY25 Q1 -99.0%
FY25 Q2 -86.1%
FY25 Q3 -77.7%
FY25 Q4 -59.7%
FY26 Q1 -62.4%
FY26 Q2 -67.7%
FCF margin (TTM) Trisalus Life Sciences, Inc.
-400% -300% -200% -100% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -313.0% FCF margin (TTM), FY23 Q4: -276.4% FCF margin (TTM), FY24 Q1: -234.7% FCF margin (TTM), FY24 Q2: -225.6% FCF margin (TTM), FY24 Q3: -167.3% FCF margin (TTM), FY24 Q4: -139.9% FCF margin (TTM), FY25 Q1: -110.5% FCF margin (TTM), FY25 Q2: -81.3% FCF margin (TTM), FY25 Q3: -55.1% FCF margin (TTM), FY25 Q4: -41.9% FCF margin (TTM), FY26 Q1: -45.2% FCF margin (TTM), FY26 Q2: -51.6% -51.6%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -313.0%
FY23 Q4 -276.4%
FY24 Q1 -234.7%
FY24 Q2 -225.6%
FY24 Q3 -167.3%
FY24 Q4 -139.9%
FY25 Q1 -110.5%
FY25 Q2 -81.3%
FY25 Q3 -55.1%
FY25 Q4 -41.9%
FY26 Q1 -45.2%
FY26 Q2 -51.6%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 12 19 29 45 45
Gross profit 10 16 25 38 39
EBITDA −36 −54 −35 −26 −30
Operating income −36 −54 −36 −27 −31
Net income −47 −59 −30 −39 −28
Diluted EPS −$161.55 −$6.77 −$1.31 −$1.84 −$0.56
Growth (year on year)
Revenue — +49.3% +59.0% +53.4% +25.2%
Margins
Gross margin 81.8% 85.9% 86.1% 84.6% 85.8%
EBITDA margin −290.7% −290.6% −120.4% −58.3% −66.4%
Operating margin −293.9% −294.3% −122.9% −59.7% −67.7%
Net margin −380.6% −320.7% −102.1% −86.9% −62.6%
Free-cash-flow margin −265.9% −276.4% −139.9% −41.9% −51.6%
Cash flow
Cash from operations −32 −51 −41 −18 −23
Capital spending 1 1 0 1 0
Free cash flow −33 −51 −41 −19 −23
Stock-based pay 0 1 5 9 11
Free cash flow after stock pay −33 −53 −47 −28 −34
Balance sheet
Cash 9 12 9 20 46
Total debt 1 0 22 33 33
Net debt (negative = net cash) −8 −12 14 13 −13
Diluted shares — 9m 25m 38m 50m
Returned to shareholders
Buybacks 232 — — — —
Total returned 232 — — — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

3 of 6 checks passed · June 30, 2026
What it owns · $62m
Short-term assets $60mLonger-term assets $3m
What it owes, and who funded it · $62m
Short-term liabilities $11mLonger-term liabilities $45mShareholders' equity $7m
  • Short-term assets cover short-term liabilities $60m of assets due within a year against $11m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $60m short-term assets against $45m of longer-dated liabilities.
  • More cash than debt $46m of cash against $33m of debt.
  • Debt below 40% of shareholders' equity Debt is 505% of equity.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt −$23m of operating cash flow against $33m of debt.
  • Operating profit covers interest at least five times over Operating income of −$31m against $6m of interest.

From Trisalus Life Sciences, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+73.8%
year over year
R&D spending
31.3%
of revenue
Days sales outstanding
52 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care equipment
Last 12 months unless stated TLSI KRMD CLPT SNWV MYO SENS Median
Revenue, last 12 months $45m $45m $45m $44m $43m $49m $99m
Revenue growth, last 12 months 25.2% 22.4% 32.5% 12.7% 6.1% 90.6% 9.2%
Revenue growth, 3-year average 45.1% 15.3% 26.8% 34.4% 35.4% 38.0% 13.5%
Revenue growth, latest quarter 1.7% 18.2% 36.3% −3.1% 21.3% 117.8% 10.2%
Gross margin 85.8% 62.4% 61.4% 76.3% 68.4% 54.9% 61.2%
Operating margin −67.7% −3.7% −70.6% 3.4% −27.1% −223.2% −8.5%
Operating margin, 3-year average −122.3% −13.3% −66.2% 7.0% −31.6% −261.7% −17.9%
Net margin −62.6% −4.0% −79.4% 34.7% −33.5% −225.3% −12.0%
Cash from operations / revenue −50.6% 3.1% −103.6% 11.9% −16.4% −197.6% −1.9%
Free-cash-flow margin −51.6% 1.6% −105.9% 9.6% −19.2% −199.5% −3.9%
Free-cash-flow margin, 3-year average −119.5% −2.7% −58.5% −0.8% −31.0% −230.3% −7.0%
Stock pay / revenue 23.6% 6.1% 18.4% 13.4% 6.4% 23.2% 6.1%
Change in share count 73.8% 2.5% 6.7% 78.4% 5.9% −2.8% 4.0%

Median of all 134 companies we cover in health care equipment. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

134 health care equipment companies
Measure Company Peer median Rank
Revenue growth Growth 25.2% 9.1% 31 of 129
Change in growth rate Growth -14.4pp -0.6pp 113 of 129
Gross margin Profitability 85.8% 61.9% 13 of 123
Operating margin Profitability -67.7% -8.3% 93 of 132
Net margin Profitability -62.6% -12.0% 92 of 133
Free-cash-flow margin Cash generation -51.6% -3.4% 95 of 128
Stock pay as % of revenue Cash generation 23.6% 6.1% 102 of 123
Long-term debt as % of assets Balance sheet 52.9% 24.2% 77 of 87
Change in share count Balance sheet 73.8% 3.3% 111 of 115
Days sales outstanding Balance sheet 52 days 57 days 49 of 118

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$104M
Institutions reporting
79
Shares held vs prior quarter
▲ 8.3%
Positions opened / closed
11 / 15

Top buyers and sellers, Q2 2026: 56 institutions bought and 25 sold ; the biggest buyer was First Light Asset Management, LLC (+1.5M shares) and the biggest seller Awm Investment Company, Inc (−2.1M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
First Light Asset Management, LLC $29.8M 6.6M 28.8% ▲ 29.3%
Blackrock, Inc. $12.1M 2.7M 11.7% ▲ 77.3%
Nantahala Capital Management, LLC $9.1M 2.0M 8.8% ▼ 3.4%
Vanguard Capital Management LLC $7.9M 1.7M 7.6% ▲ 28.4%
Cerity Partners LLC $7.3M 1.6M 7.0% ▲ 103.7%
Geode Capital Management, LLC $5.4M 1.2M 5.2% ▲ 53.1%
Gilder Gagnon Howe & Co LLC $3.9M 850K 3.7% ▼ 4.3%
State Street Corp $2.8M 611K 2.7% ▲ 86.3%
White Pine Capital LLC $2.5M 548K 2.4% ▲ 50.6%
Thompson Siegel & Walmsley LLC $2.4M 537K 2.4% ▼ 8.1%
Kennedy Capital Management LLC $2.2M 476K 2.1% ▼ 1.9%
Morgan Stanley $1.8M 402K 1.8% ▲ 2.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Trisalus Life Sciences, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $3.6M 12 trades by 6 insiders, last 12 months Insider sales History → $139,922 18 trades by 5 insiders · 0% under pre-set plans
Net ▲ $3.5M net buying
Insider Date Trade Shares Price Value
Stevens Jennifer Chief Regulatory Officer October 5, 2026 Sell 316 $4.39 $1,387
Marshak Richard Chief Commercial Officer October 5, 2026 Sell 325 $4.39 $1,427
Cox Bryan F. Chief of Research October 5, 2026 Sell 296 $4.39 $1,299
Gordon Gary B. Director May 15, 2026 Buy 10,000 $2.46 $24,600
Patience David Chief Financial Officer May 15, 2026 Buy 7,100 $2.43 $17,253
Szela Mary T CEO and President May 15, 2026 Buy 39,682 $2.59 $102,776
Stansky Michael P Director May 15, 2026 Buy 200,000 $2.50 $500,000
Stansky Michael P Director May 15, 2026 Buy 410,000 $2.50 $1M
Wahlstrom Mats Director May 15, 2026 Buy 60,000 $2.53 $151,800
Marshak Richard Chief Commercial Officer May 15, 2026 Sell 543 $2.67 $1,450
Szela Mary T CEO and President March 17, 2026 Sell 15,944 $3.85 $61,384
Stevens Jennifer Chief Regulatory Officer March 16, 2026 Sell 774 $4.12 $3,189

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

  • August 6, 2026
  • May 12, 2026
  • March 5, 2026
  • January 12, 2026
  • November 13, 2025
  • August 12, 2025

Recent SEC filings

Data status

When each part of this page on Trisalus Life Sciences, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Trisalus Life Sciences, Inc. in brief

What does Trisalus Life Sciences, Inc. do?
Trisalus Life Sciences, Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.
What is Trisalus Life Sciences, Inc.'s stock ticker?
Trisalus Life Sciences, Inc. trades under the ticker TLSI on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Trisalus Life Sciences, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Trisalus Life Sciences, Inc. reported revenue of $45.1M, 25.2% higher than a year earlier, according to its SEC filings.
What is Trisalus Life Sciences, Inc.'s free cash flow?
Trisalus Life Sciences, Inc.'s free-cash-flow margin is -51.6% of revenue over the trailing twelve months, ranking 95 of the 128 health care equipment companies we cover.
Who are Trisalus Life Sciences, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are First Light Asset Management, LLC, Blackrock, Inc. and Nantahala Capital Management, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Trisalus Life Sciences, Inc.'s market cap?
On November 2, 2026, Trisalus Life Sciences, Inc.'s market capitalisation was about $182M and net debt of -$13.2M. Market figures come from third-party market data and may be delayed.
How much debt does Trisalus Life Sciences, Inc. have?
Trisalus Life Sciences, Inc.'s debt-to-equity ratio is 504.8%, from its latest balance sheet. The financial health section below sets out its other solvency checks.
Who are Trisalus Life Sciences, Inc.'s competitors?
In our Health Care Equipment peer group, the companies closest to Trisalus Life Sciences, Inc. are Koru Medical Systems, Inc., Clearpoint Neuro, Inc., Sanuwave Health, Inc., Myomo, Inc. and Senseonics Holdings, Inc. The side-by-side comparison below sets their revenue, margins and growth against Trisalus Life Sciences, Inc.'s.
Are insiders buying or selling Trisalus Life Sciences, Inc. stock?
Over the last 12 months, Trisalus Life Sciences, Inc.'s directors and officers reported 12 open-market purchases and 18 sales on Form 4. The insider trading page charts every trade.
When is Trisalus Life Sciences, Inc.'s next earnings date?
Around November 10, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Trisalus Life Sciences, Inc. announces its own schedule.